Viatris Sets The Bar Low So There Will Eventually Be A Chance To Grow
Executive Summary
Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.
You may also be interested in...
Organon Is Ready To Launch And Makes The Case To Investors
Merck & Co. plans to spin off Organon in June as a diversified health care company focused on women's health, biosimilars and established products.
Up To 9,000 Jobs At Risk As Viatris Kicks Off $1bn Restructuring Scheme
With a goal of reducing its cost base by at least $1bn by 2024, Viatris has delivered plans to significantly restructure its global manufacturing network. Up to 20% of Viatris’ 45,000-strong workforce could be impacted by the initiative which will see the firm close, divest or downsize 15 of its manufacturing plants around the globe.
Mylan Strikes €642m Deal For Aspen’s Thrombosis Business In Europe
With Mylan continuing to count down the days until its merger with Pfizer’s Upjohn completes, the US firm has struck a deal to acquire Aspen Pharmacare’s thrombosis business in Europe, bolstering what is already a $4bn operation.